Amgen and Gilead deliver lacklustre early clinical results with AMG 355 and denikitug respectively.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo.
Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity.
Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?
Having failed to get Zynyz approved in the second-line setting the group has the front line in its sights.
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.